Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of temsirolimus when given
together with sorafenib and to see how well they work in treating patients with metastatic,
recurrent, or unresectable melanoma. Sorafenib and temsirolimus may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the
growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with
temosirolimus may kill more tumor cells.